Cara Therapeutics (CARA) Tops Q4 EPS by 6c

Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• HP shares slide as tech giant forecasts 2027 PC market slump
• AMC Entertainment launches tender offer for $360M in senior notes
• KeyBanc Reiterates Overweight Rating on Brinker Int'l (EAT)